Cargando…

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease

BACKGROUND: Gait impairments are common in patients with Alzheimer’s disease. Cholinesterase inhibitors are used to treat the symptoms of patients with Alzheimer’s disease, but they have not been shown to reduce the severity of Alzheimer’s disease-related gait disorders. METHODS: This was a prospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimura, Hideki, Saiko, Aiba, Hayashi, Akito, Hattori, Nobutaka, Urabe, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874473/
https://www.ncbi.nlm.nih.gov/pubmed/33568083
http://dx.doi.org/10.1186/s12883-021-02098-8
_version_ 1783649595015823360
author Shimura, Hideki
Saiko, Aiba
Hayashi, Akito
Hattori, Nobutaka
Urabe, Takao
author_facet Shimura, Hideki
Saiko, Aiba
Hayashi, Akito
Hattori, Nobutaka
Urabe, Takao
author_sort Shimura, Hideki
collection PubMed
description BACKGROUND: Gait impairments are common in patients with Alzheimer’s disease. Cholinesterase inhibitors are used to treat the symptoms of patients with Alzheimer’s disease, but they have not been shown to reduce the severity of Alzheimer’s disease-related gait disorders. METHODS: This was a prospective, single-arm, open-label, non-randomized study. The aim of the present study was to determine the effect of the acetylcholinesterase inhibitor rivastigmine on gait in 21 newly diagnosed patients with mild to moderate Alzheimer’s disease. The outcome variables were velocity, stride length, and cadence during single-task and dual-task gait trials. The subjects were also assessed with the Mini-Mental State Examination, Alzheimer’s Disease Cooperative Study Activities of Daily Living, Functional Assessment Staging, and Geriatric Depression Scale. RESULTS: After 12 weeks of treatment with rivastigmine, gait velocity was significantly improved in the dual-task gait trials; gait velocity was increased from 40.59 ± 13.59 m/min at baseline to 46.88 ± 12.73 m/min when counting backward from 100 in steps of 7 while walking, and gait velocity was increased from 37.06 ± 15.57 m/min at baseline to 42.03 ± 14.02 m/min when naming animals while walking. In the single-task gait trials, which consisted only of walking at their usual pace or at a fast pace, gait velocity was not increased by rivastigmine administration. CONCLUSION: Our findings indicated that rivastigmine improved gait in subjects with mild to moderate Alzheimer’s disease during dual-task trials. The observed enhancement of dual-task gait might be caused by an improvement of cognitive function rather than motor function. TRIAL REGISTRATION: UMIN, UMIN000025869. Registered December 16, 2016, https://upload.umin.ac.jp/cgi-open-bin/icdr/ctr_view.cgi?recptno=R000029744
format Online
Article
Text
id pubmed-7874473
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78744732021-02-11 Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease Shimura, Hideki Saiko, Aiba Hayashi, Akito Hattori, Nobutaka Urabe, Takao BMC Neurol Research Article BACKGROUND: Gait impairments are common in patients with Alzheimer’s disease. Cholinesterase inhibitors are used to treat the symptoms of patients with Alzheimer’s disease, but they have not been shown to reduce the severity of Alzheimer’s disease-related gait disorders. METHODS: This was a prospective, single-arm, open-label, non-randomized study. The aim of the present study was to determine the effect of the acetylcholinesterase inhibitor rivastigmine on gait in 21 newly diagnosed patients with mild to moderate Alzheimer’s disease. The outcome variables were velocity, stride length, and cadence during single-task and dual-task gait trials. The subjects were also assessed with the Mini-Mental State Examination, Alzheimer’s Disease Cooperative Study Activities of Daily Living, Functional Assessment Staging, and Geriatric Depression Scale. RESULTS: After 12 weeks of treatment with rivastigmine, gait velocity was significantly improved in the dual-task gait trials; gait velocity was increased from 40.59 ± 13.59 m/min at baseline to 46.88 ± 12.73 m/min when counting backward from 100 in steps of 7 while walking, and gait velocity was increased from 37.06 ± 15.57 m/min at baseline to 42.03 ± 14.02 m/min when naming animals while walking. In the single-task gait trials, which consisted only of walking at their usual pace or at a fast pace, gait velocity was not increased by rivastigmine administration. CONCLUSION: Our findings indicated that rivastigmine improved gait in subjects with mild to moderate Alzheimer’s disease during dual-task trials. The observed enhancement of dual-task gait might be caused by an improvement of cognitive function rather than motor function. TRIAL REGISTRATION: UMIN, UMIN000025869. Registered December 16, 2016, https://upload.umin.ac.jp/cgi-open-bin/icdr/ctr_view.cgi?recptno=R000029744 BioMed Central 2021-02-10 /pmc/articles/PMC7874473/ /pubmed/33568083 http://dx.doi.org/10.1186/s12883-021-02098-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Shimura, Hideki
Saiko, Aiba
Hayashi, Akito
Hattori, Nobutaka
Urabe, Takao
Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
title Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
title_full Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
title_fullStr Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
title_full_unstemmed Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
title_short Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
title_sort rivastigmine improves dual-task gait velocity in patients with alzheimer’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874473/
https://www.ncbi.nlm.nih.gov/pubmed/33568083
http://dx.doi.org/10.1186/s12883-021-02098-8
work_keys_str_mv AT shimurahideki rivastigmineimprovesdualtaskgaitvelocityinpatientswithalzheimersdisease
AT saikoaiba rivastigmineimprovesdualtaskgaitvelocityinpatientswithalzheimersdisease
AT hayashiakito rivastigmineimprovesdualtaskgaitvelocityinpatientswithalzheimersdisease
AT hattorinobutaka rivastigmineimprovesdualtaskgaitvelocityinpatientswithalzheimersdisease
AT urabetakao rivastigmineimprovesdualtaskgaitvelocityinpatientswithalzheimersdisease